Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 114Breast Neoplasms 79Neoplasms 74Neoplasm Metastasis 63Colorectal Neoplasms 62Prostatic Neoplasms 57Recurrence 56Pancreatic Neoplasms 55Leukemia, Myeloid, Acute 55Ovarian Neoplasms 53Multiple Myeloma 50Melanoma 39Glioblastoma 38Squamous Cell Carcinoma of Head and Neck 33Lung Neoplasms 33Triple Negative Breast Neoplasms 31Lymphoma, Non-Hodgkin 30Endometrial Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Lymphoma 27Carcinoma, Renal Cell 27Lymphoma, Large B-Cell, Diffuse 26Stomach Neoplasms 25Lymphoma, B-Cell 25Carcinoma, Hepatocellular 24Advanced Solid Tumor 24Small Cell Lung Carcinoma 23Leukemia, Lymphocytic, Chronic, B-Cell 23Burkitt Lymphoma 23Brain Neoplasms 23

Interventions

resiniferatoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pain, Intractable × 90 days × Clear all
NCT02522611 2026-06-01

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

National Institutes of Health Clinical Center (CC)

Phase 1/2 Not yet recruiting
30 enrolled

Cancer Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡